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Seven different serotypes of botulinum neurotoxins (BoNTs) have been identified, but only serotypes A and B are commercially available for use in clinical practice.[1](#mdc312235-bib-0001){ref-type="ref"}, [2](#mdc312235-bib-0002){ref-type="ref"}, [3](#mdc312235-bib-0003){ref-type="ref"}, [4](#mdc312235-bib-0004){ref-type="ref"}, [5](#mdc312235-bib-0005){ref-type="ref"} Currently, three different BoNTs of serotype A (BoNTs‐A) have been approved in the United States for various clinical applications in aesthetics and dermatological, neurological, and urological indications.[1](#mdc312235-bib-0001){ref-type="ref"}, [6](#mdc312235-bib-0006){ref-type="ref"} These preparations are Botox (onabotulinumtoxinA \[ONA\]; Allergan, Inc., Irvine, CA),[2](#mdc312235-bib-0002){ref-type="ref"} Dysport (abobotulinumtoxinA \[ABO\]; Ipsen Biopharmaceuticals, Inc., Basking Ridge, NJ),[3](#mdc312235-bib-0003){ref-type="ref"} and Xeomin (incobotulinumtoxinA \[INCO\]; Merz Pharmaceuticals, LLC; Greensboro, NC).[5](#mdc312235-bib-0005){ref-type="ref"}

BoNTs‐A have been used therapeutically for more than 20 years throughout the world.[1](#mdc312235-bib-0001){ref-type="ref"}, [2](#mdc312235-bib-0002){ref-type="ref"} In the United States, ONA is available in 50‐, 100‐, and 200‐unit (U) vials,[2](#mdc312235-bib-0002){ref-type="ref"}, [7](#mdc312235-bib-0007){ref-type="ref"} and ABO is available in 300‐ and 500‐U vials.[3](#mdc312235-bib-0003){ref-type="ref"} Each unit of BoNT corresponds to the calculated intraperitoneal median lethal dose (LD~50~) of reconstituted product in a biological mouse model.[8](#mdc312235-bib-0008){ref-type="ref"} Many factors affect the LD~50~ bioassay, including type of assay used,[8](#mdc312235-bib-0008){ref-type="ref"} mouse strain, gender and age, route and volume of injection, time of examination postinjection,[9](#mdc312235-bib-0009){ref-type="ref"} and delivery vehicle or reconstitution buffer.[10](#mdc312235-bib-0010){ref-type="ref"} Because the commercial BoNTs are produced by different pharmaceutical laboratories using different proprietary methodologies and assay methods, the potency of a unit of one product is not equivalent to a unit of another, and the unit potencies of different BoNT formulations cannot be easily compared.[8](#mdc312235-bib-0008){ref-type="ref"}, [9](#mdc312235-bib-0009){ref-type="ref"}, [10](#mdc312235-bib-0010){ref-type="ref"}, [11](#mdc312235-bib-0011){ref-type="ref"}, [12](#mdc312235-bib-0012){ref-type="ref"}, [13](#mdc312235-bib-0013){ref-type="ref"}, [14](#mdc312235-bib-0014){ref-type="ref"}

Although the unit doses of BoNT products are not interchangeable, clinicians are required to estimate the approximate dose equivalence between BoNTs‐A when changes are warranted owing to secondary nonresponse, development of side effects, or changes in insurance coverage.

Multiple studies have been performed to establish the comparative potency of ONA and ABO, but the issue remains unresolved and controversial.[9](#mdc312235-bib-0009){ref-type="ref"}, [10](#mdc312235-bib-0010){ref-type="ref"}, [11](#mdc312235-bib-0011){ref-type="ref"}, [12](#mdc312235-bib-0012){ref-type="ref"}, [13](#mdc312235-bib-0013){ref-type="ref"}, [14](#mdc312235-bib-0014){ref-type="ref"} Investigators have compared ONA:ABO at conversion ratios ranging from 1:1 to 1:13.3.[15](#mdc312235-bib-0015){ref-type="ref"}, [16](#mdc312235-bib-0016){ref-type="ref"} Currently, among experts, dose conversions range from 1:1.5 to 1:4, although without definitive support. The few head‐to‐head studies have had different methodologies and outcomes, diminishing their individual value for wider clinical application.

Because ONA and ABO share the same BoNT serotype, and because no strong evidence exists to suggest differences in local or distant spreading or in efficacy between products,[17](#mdc312235-bib-0017){ref-type="ref"} we sought to establish the collective safest and most effective conversion dose between ONA and ABO across all available head‐to‐head randomized, controlled trials in movement disorders.

Materials and Methods {#mdc312235-sec-0006}
=====================

We conducted a systematic literature review of clinical trials comparing ONA to ABO for therapeutic uses in any of the medical fields in which these toxins have been examined. The primary aim was to examine dosing practices, dosing conversions, and related outcomes from selected studies in order to produce the tightest estimate of the conversion ratio between these two BoNTs‐A.

Literature Search Strategy {#mdc312235-sec-0007}
--------------------------

Based on the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA), a literature search strategy and methods for systematic review were specified in advance of data collection. The authors agreed upon a PRISMA search strategy that they felt would identify the highest‐quality data available in the medical literature to recommend a dose conversion ratio between ONA and ABO. The systematic literature review focused on identifying comparative clinical studies, systematic reviews, and meta‐analyses across countries. The search was intended to capture all ONA versus ABO clinical trials within the following conditions of interest: movement disorders (head/neck); movement disorders (face/eye); movement disorders (jaw/tongue/mouth); spasticity (all limbs); focal limb/other dystonia; sweating; pain; and aesthetics (glabellar lines or crow\'s feet). Only studies with movement disorder applications were included for this systematic literature review.

The authors agreed on a strategy that used a combination of Medical Subject Heading (MeSH) terms and key words. The initial terms for inclusion were the indications as well as the terms onabotulinumtoxinA (with alternative spellings onabotulinumtoxin A and onabotulinum toxin A), Botox, abobotulinumtoxinA (with alternative spellings abobotulinumtoxin A and abobotulinum toxin A), Dysport, and clinical trial. Studies that were published in languages other than English or outside the date range (January 1991 to January 2015) were excluded. The search was performed in three electronic medical literature databases: PubMed, the Cochrane Library, and EMBASE.

Study Selection {#mdc312235-sec-0008}
---------------

At level 1 screening, titles and abstracts identified from the electronic databases were reviewed by two researchers independently (K.D. and J.C.) to evaluate potential study relevance. All publications reporting preclinical, phase I, prognostic/biomarker, genetic retrospective, registry, case report, and/or noncomparative studies were excluded, as were letters, consensus reports, editorials, and nonsystematic reviews. At level 2 screening, full‐text studies selected at level 1 were reviewed with the same inclusion and exclusion criteria. In addition, bibliographical references of systematic reviews and meta‐analyses were searched to find relevant studies that may not have been identified during the primary search. At both screening levels, the authors met to reach consensus about any cases where there was initial disagreement or uncertainty about study inclusion. The overall study‐selection process is illustrated in Figure [1](#mdc312235-fig-0001){ref-type="fig"}.

![PRISMA flow diagram reporting the results of the systematic literature search. Level 1 screening = review of titles and abstracts; Level 2 screening = review of full‐text articles; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta‐Analyses.](MDC3-3-109-g001){#mdc312235-fig-0001}

Data Extraction and Bias Assessment {#mdc312235-sec-0009}
-----------------------------------

After screening, randomized, controlled clinical trials that met the predefined inclusion criteria were selected for formal data extraction and quality assessment. Data were extracted from the full‐text publications under the following predefined headings: Study Title, Sponsor, Methodology, Patients, Treatment, Efficacy Results (primary and secondary endpoints), Safety Results, Conclusion. Each study underwent quality assessment of risk for bias based on Cochrane metrics, which addressed six types of potential bias: selection, performance, detection, attrition, reporting, and other sources of bias not covered by other domains.[18](#mdc312235-bib-0018){ref-type="ref"}

Determination of Appropriate Dose Conversion {#mdc312235-sec-0010}
--------------------------------------------

For the purposes of this review, we defined a comparable dose conversion as one in which the efficacy and safety were equivalent (i.e., no statistically significant difference) between ONA and ABO. If differences in efficacy and/or safety were observed between ONA and ABO in the study, we concluded that the dose conversion ratio was not comparable.

Results {#mdc312235-sec-0011}
=======

A total of 182 manuscripts were identified during the level 1 screening. Of these, 112 records were excluded based on titles and abstracts, and 70 full‐text articles were retrieved. After level 2 screening, 14 primary publications were included for data extraction and analysis. Upon data extraction, it became clear that two of these were duplicates of the same study,[19](#mdc312235-bib-0019){ref-type="ref"}, [20](#mdc312235-bib-0020){ref-type="ref"} leaving 13 studies for the analysis. Of these 13 studies, only the four movement disorder studies were included for the current systematic review analyses owing to the fact that the dosage, efficacy, and profile of adverse effects can be different from the nonmovement disorders indications of botulinum toxins.

In the quality assessment of risk for bias for the studies that compared ONA and ABO for the treatment of movement disorders, the studies fulfilled the Cochrane criteria for low risk (n = 2) or unclear risk (n = 2) of bias.

Of the four studies meeting criteria for final analysis, one compared ONA and ABO at a dose conversion ratio of 1:2.5[23](#mdc312235-bib-0023){ref-type="ref"} and two compared the toxins at a 1:3 dose conversion.[21](#mdc312235-bib-0021){ref-type="ref"}, [22](#mdc312235-bib-0022){ref-type="ref"} One of the 1:3 studies also had a 1:4 arm.[22](#mdc312235-bib-0022){ref-type="ref"} The fourth study included in the final analysis also compared the toxins using a 1:4 dose conversion ratio.[24](#mdc312235-bib-0024){ref-type="ref"}

Clinical Trials for Cervical Dystonia {#mdc312235-sec-0012}
-------------------------------------

Three randomized, clinical trials compared ONA and ABO for cervical dystonia (Table S1). Odergren et al. evaluated the dose equivalence of ONA and ABO at a conversion ratio of 1:3 in a double‐blind, randomized, parallel‐group study of 73 patients treated for predominantly rotational cervical dystonia. The toxins were administered to one or more affected muscles, at one or more sites per muscle.[21](#mdc312235-bib-0021){ref-type="ref"} Patients in both groups experienced substantial improvement in Tsui scores by week 2, with a peak effect at week 4. The mean post‐treatment Tsui scores for the two groups were not statistically different (*P* = 0.66), and there were no significant differences in the incidence rates of adverse events (*P* = 0.35). Overall, there was no significant difference in the number of treatment successes between groups based on a global assessment of efficacy and safety (76% ABO; 66% ONA; *P* = 0.32). The authors concluded that patients with predominantly rotational cervical dystonia had similar improvements and experienced similar safety profiles when treated with ONA or ABO at a 1:3 conversion ratio.[21](#mdc312235-bib-0021){ref-type="ref"}

Ranoux et al. evaluated patients with cervical dystonia in a double‐blind, randomized, cross‐over study designed to compare the efficacy and safety of ONA with ABO at two conversion ratios.[22](#mdc312235-bib-0022){ref-type="ref"} In a random order, patients received ONA at the usually effective dose for the patient, ABO at a conversion ratio of 1:3, and ABO at a conversion ratio of 1:4. In the study, patients treated with ABO had significantly better improvement in Tsui score at both conversion ratios compared to patients in the ONA group. The mean change from baseline to 1 month postinjection was 3.25 for the ONA group, 4.27 for the ABO 1:3 conversion, and 4.92 for the ABO 1:4 conversion (*P* = 0.02 and 0.01 for the 1:3 and 1:4 conversions, respectively). The mean duration of action was not significantly different between ONA and ABO at the 1:3 conversion ratio (89.3 vs. 96.9 days; *P* = 0.58), but at the 1:4 conversion, ABO had a significantly longer duration (89.3 vs. 114 days; *P* = 0.02). The number of adverse events was higher with both ABO treatments. The most frequent event was dysphagia, which occurred in 3%, 15.6%, and 17.3% of patients in the ONA, ABO 1:3, and ABO 1:4 groups, respectively. The authors concluded that ABO is more effective than ONA for cervical dystonia, but with a higher incidence of adverse effects.[22](#mdc312235-bib-0022){ref-type="ref"}

Yun et al. compared ONA with ABO at a dose conversion ratio of 1:2.5 in 103 patients with cervical dystonia in a randomized, double‐blind, noninferiority cross‐over trial (Table S1).[23](#mdc312235-bib-0023){ref-type="ref"} Patients were assessed at baseline and follow‐up using the Tsui scale and the Toronto western spasmodic torticollis rating scale (TWSTRS). In the study, no significant differences between ONA and ABO treatment were observed from baseline to assessment at 1 month in Tsui scales scores (−4.77 vs. −3.98; *P* = 0.091) or TWSTRS (−8.78 vs. −9.76; *P* = 0.429). In addition, no significant differences in clinical global impression or patient global impression were identified. Muscle weakness and dysphagia were the most common adverse events with both treatments, and no significant differences were observed in the incidence of adverse events between treatments.[23](#mdc312235-bib-0023){ref-type="ref"}

Clinical Trial for Blepharospasm {#mdc312235-sec-0013}
--------------------------------

One randomized, clinical trial compared ONA and ABO for essential blepharospasm (Table S1). Nussgens and Roggenkamper found that a dose conversion ratio of 1:4 was associated with similar duration of effect for both drugs (extent of improvement in blepharospasm was not reported), but patients in the ABO group had higher rates of adverse events.[24](#mdc312235-bib-0024){ref-type="ref"} Thus, the ONA‐to‐ABO ratio of 1:4 appeared noncomparable, with data in this study limited to a trade‐off between duration and adverse events.

Summary Results of Dose Conversion Ratios {#mdc312235-sec-0014}
-----------------------------------------

The outcomes of the clinical trials by dose conversion ratio and indication are shown in Figure [2](#mdc312235-fig-0002){ref-type="fig"}. The two randomized, clinical trials (total, n = 264) that compared ONA and ABO at a dose conversion ratio of 1:4 were both associated with greater occurrence of adverse effects with ABO.[22](#mdc312235-bib-0022){ref-type="ref"}, [24](#mdc312235-bib-0024){ref-type="ref"} In one of the trials (n = 73) that used a 1:3 dose conversion, efficacy and safety did not differ between ABO and ONA.[21](#mdc312235-bib-0021){ref-type="ref"} In the other trial (n = 51) that used a 1:3 dose conversion, treatment with ABO resulted in higher efficacy and higher rates of adverse events.[22](#mdc312235-bib-0022){ref-type="ref"} In the trial (n = 103) that used a 1:2.5 dose conversion, ABO was associated with similar efficacy and adverse events.[23](#mdc312235-bib-0023){ref-type="ref"}

![Distribution of studies by indication, dose conversion ratio, and outcomes. Note: the sizes of the circles reflect number of subjects in each study.](MDC3-3-109-g002){#mdc312235-fig-0002}

Discussion {#mdc312235-sec-0015}
==========

The converging evidence from BoNT comparative clinical trials suggests that a dose conversion ratio of ONA to ABO between 1:2.5 and 1:3 provides comparable safety and efficacy for therapeutic movement disorders chemodenervation procedures. A conversion ratio of 1:4 appears to yield an undesirable trade‐off between greater efficacy/longer duration and poorly tolerable side effects.

Whereas the unit doses of different BoNTs are not interchangeable owing to differences in proprietary manufacturing methodologies and assays, chemodenervation in a variety of clinical settings requires making informed inter‐BoNT conversion decisions. We performed this systematic review to develop a detailed summary of the dosing practices, dosing conversions, and related outcomes from randomized, controlled trials that compared use of ABO to ONA for movement disorders. The data reviewed herein serve to establish an appropriate conversion dose ratio for ABO and ONA based on the best available evidence.

For the purposes of this review, we defined a comparable conversion dose as one in which the safety and efficacy results did not differ for patients treated with ABO or ONA. A noncomparable conversion may result from disproportionate rates of adverse events, most notably dysphagia.[22](#mdc312235-bib-0022){ref-type="ref"}

In addition to conversion ratios based on efficacy and tolerability, dose conversions may need to factor in cost‐effectiveness differences between toxins, which cannot be adequately extracted from the controlled clinical trials selected here. Because BoNTs are widely used around the world for multiple indications, optimizing the cost per injection may have a substantial impact on costs for the individual patient as well as the overall health care system.

Conclusion {#mdc312235-sec-0016}
==========

In this systematic review, we found that ONA:ABO dose conversion ratios above 1:3 significantly increased rates of adverse events in patients treated with ABO and should be discouraged. Overall, a dose conversion of 1:2.5 resulted in equivalent or lower rates of adverse events, with equivalent or, in some cases, lower efficacy associated with ABO. In the two studies using a dose conversion of 1:3, ABO was as effective as or more effective than ONA and associated with equivalent (one study) or higher (one study) occurrence of adverse effects.

In summary, data extracted from randomized, clinical studies suggest that a dose conversion of 2.5 to no more than 3 U of ABO for each unit of ONA provides an appropriate balance of safety and efficacy. However, the most appropriate dose ratio when switching from one BoNT to another depends on multiple factors, including the severity of patients\' symptoms, any comorbid conditions, and previous response to BoNT treatment.
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